Abstract
Objective: Misapplication of the 2016 Centers for Disease Control (CDC) opioid prescribing guidelines has led to overemphasis of morphine-equivalent daily dose (MEDD) as a “metric of success” in chronic noncancer pain (CNCP), resulting in unintentional harms to patients. This article reviews CNCP-related guidelines and patient preferences in order to identify pragmatic, patient-centered metrics to assess treatment response and safety in opioid-treated CNCP. Methods: We reviewed the clinical (CDC), research (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials), and implementability-related guidelines (GuideLine Implementability Appraisal), along with relevant patient-identified treatment goals. From these, we summarize a guideline-concordant, patient-centered, implementable set of measures to aid the clinical management of opioid-treated CNCP. Results: We identify metrics across three domains of care: (1) treatment response metrics, which align with the CNCP care goals (pain intensity, pain interference including function and quality of life, and global impression of change); (2) risk assessment (“safety”) metrics, eg, MEDD, benzodiazepine-opioid or naloxone-opioid coprescribing, and severity of mental health disorders, which evaluate the risk-benefit profile of opioid therapy; and (3) adherence (“process”) metrics, which assess clinician/patient adherence to the guideline-recommended opioid therapy monitoring practices, eg, the presence of completed treatment agreement or urine toxicology testing. All metrics should be informed by implementability principles, eg, be decidable, executable, and measurable. Conclusions: This article summarizes guideline-concordant, patient-centered, implementable metrics for assessing treatment response, safety, and adherence in opioid-treated CNCP. Regardless of which specific treatment guidelines are applied, this approach could help conceptualize and standardize the collection and reporting of CNCP-relevant metrics, compare them across health systems, and optimize care and treatment outcomes in opioid-treated CNCP.
Publisher
Weston Medical Publishing
Subject
Anesthesiology and Pain Medicine,Pharmacology (medical),General Medicine
Reference47 articles.
1. Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016; 65(1): 1-49. DOI: 10.15585/mmwr.rr6501e1.
2. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control: Quality improvement (QI) and care coordination: Implementing the CDC guideline for prescribing opioids for chronic pain. 2021. Available at https://www.cdc.gov/opioids/healthcare-admins/pdf/Quality-Improvement-Care-Coordination-508.pdf. Accessed October 4, 2023.
3. Stone W, Huang P: CDC issues new opioid prescribing guidance, giving doctors more leeway to treat pain. NPR. 2022. Available at https://www.npr.org/sections/healthshots/2022/11/03/1133908157/new-opioid-prescribing-guidelines-give-doctors-more-leeway-to-treat-pain. Accessed September 11, 2023.
4. Busse JW, Juurlink D, Guyatt GH: Addressing the limitations of the CDC guideline for prescribing opioids for chronic noncancer pain. CMAJ. 2016; 188(17-18): 1210-1211. DOI: 10.1503/cmaj.161023.
5. Busse JW, Craigie S, Juurlink DN, et al.: Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017; 189(18): E659-E666. DOI: 10.1503/cmaj.170363.